Thus, to date, none of these biologics have an established use in clinical practice for the treatment of SLE, with the exception for Rituximab, a monoclonal antibody to the CD20 antigen expressed on B cells, and Belimumab, a monoclonal antibody to B-cell activating factor (BAFF), that have demonstrated improvements in controlling the worst manifestation of SLE, the lupus nephritis [75]. This evidence concerns the gene TNFSF13B and lupus nephritis.